The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics
Abstract
The pharmacokinetics and toxicity of albendazole, mebendazole and praziquantel are extensively reviewed, drawing on original published work and reviews in the open scientific literature and on assessments by international agencies and official regulatory bodies in Europe and the USA. Information about human and veterinary medical uses and adverse reactions is evaluated. The totality of the non-clinical information available about these long-established drugs may not comply with current official guidelines for new medicines but reasons are given why the "deficiencies" are only apparent and the data gaps can be replaced by other results, largely obtained from the target species and the many years of clinical experience of safe use of these drugs in humans and animals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, albendazole sulfoxide, among 5 metabolites of albendazole detected in human urine, is considered the major metabolite responsible for the anthelmintic activity [3,6].”
From Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update (2021) · cites this paper as [3]
In the citing paper
“The absorption rate of oral albendazole and mebendazole in human intestine is about 1–5% [3].”
From Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update (2021) · cites this paper as [3]
In the citing paper
“In experimental rats, mebendazole has been shown to be a teratogen if given very high doses although not in rabbits [3].”
From Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update (2021) · cites this paper as [3]
In the citing paper
“Albendazole is contraindicated during pregnancy in humans [3,11].”
From Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update (2021) · cites this paper as [3]
In the citing paper
“Albendazole is known to be a teratogen and fetal toxicant in experimental animals at very high doses [3].”
From Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update (2021) · cites this paper as [3]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Meyler's Side Effects of Drugs
Breckenridge, A. M. (1976) · BMJ · doi:10.1136/bmj.2.6030.307 · Cited by 691
Andrews, P., Thomas, H., Pohlke, R., & Seubert, J. (1983) · Medicinal Research Reviews · doi:10.1002/med.2610030204 · Cited by 365
Textbook of Adverse Drug Reactions.
(1981) · Annals of Internal Medicine · doi:10.7326/0003-4819-95-5-667_1 · Cited by 337
The metabolism of benzimidazole anthelmintics
Gottschall, D. W., Theodorides, V. J., & Wang, R. (1990) · Parasitology Today · doi:10.1016/0169-4758(90)90228-v · Cited by 172
Aneuploidy: a report of an ECETOC task force
Aardema, M. J. (1998) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(97)00029-x · Cited by 151
Rawden, H. C., Kokwaro, G. O., Ward, S. A., &, & Edwards, G. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00170.x · Cited by 146
Metabolism of albendazole in cattle, sheep, rats and mice.
Gyurik, R. J., Chow, A. W., Zaber, B., Brunner, E. L., Miller, J. A., Villani, A. J., Petka, L. A., & Parish, R. C. (1981) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06560-2 · Cited by 127
Clinical Pharmacokinetics of Anthelmintic Drugs
Edwards, G., & Breckenridge, A. M. (1988) · Clinical Pharmacokinetics · doi:10.2165/00003088-198815020-00001 · Cited by 104
Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease
Braithwaite, P., Roberts, M. S., Allan, R., & Watson, T. R. (1982) · European Journal of Clinical Pharmacology · doi:10.1007/bf00542462 · Cited by 99
Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis
Mandour, M. E. M., Elturabi, H., Homeida, M. M. A., Sadig, T., Ali, H. M., Bennett, J. L., Leahey, W. J., & Harron, D. W. G. (1990) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(90)90333-a · Cited by 95
Research works printed but not linked: 12
- Amri, 1988, Albendazole sulfonation by rat liver P-450c, J. Pharmacol. Exp. Ther., 246, 758
- Bittencourt, 1982, Phenytoin and carbamezepine decrease oral bioavailability of praziquantel, Neurology, 42, 493
- Frohberg, 1982, Propriedades farmocinéticas, farmacologicas y toxicológicas, Salud Publica Mex., 24, 605
- Gray, J., 1999. Mebendazole: commentary on the mutagenic potential. Report from Covance Laboratories, Harrogate, UK, to the Janssen Research Foundation; 7th March, 1999, pp. 1–31.
- JECFA, 1989a. Albendazole: in Evaluation of Certain Veterinary Drug Residues in Food. In: Thirty-fourth Report of the Joint WHO/FAO Expert Committee on Food Additives, WHO, Geneva, pp. 14-19.
- JECFA, 1989b. Albendazole. In: JECFA Food Additives Series 25. Prepared by the Thirty-fourth Meeting of the Joint WHO/FAO Expert Committee on Food Additives, WHO, Geneva, pp. 3-29.
- Martindale's Extra Pharmacopoeia, 1993a. In: Reynolds, J.R. (Ed.), Albendazole, 30th Edition. Pharmaceutical Press, London, p. 43.
- Martindale's Extra Pharmacopoeia, 1993b. In: Reynolds, J.R. (Ed.), Mebendazole, 30th Edition. Pharmaceutical Press, London, p. 46–47.
- Martindale's Extra Pharmacopoeia, 1993c. In: Reynolds, J.R. (Ed.), Praziquantel, 30th Edition. Pharmaceutical Press, London, p. 52–53.
- PDR, 2001a. Albenza™, 55th ed. Medical Economics, NJ, pp. 3058–3059.
- PDR, 2001b. Vermox®, 55th Edition. Medical Economics, NJ, p. 1839.
- PDR, 2001c. Biltricide®, 55th Edition. Medical Economics, NJ, pp. 346–347.
Cited by
Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm
Bethony, J., Brooker, S., Albonico, M., Geiger, S. M., Loukas, A., Diemert, D., & Hotez, P. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68653-4 · Cited by 2,478
Gryseels, B., Polman, K., Clerinx, J., & Kestens, L. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69440-3 · Cited by 2,084
Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis
Doenhoff, M. J., Cioli, D., & Utzinger, J. (2008) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328318978f · Cited by 806
Loukas, A., Hotez, P. J., Diemert, D., Yazdanbakhsh, M., McCarthy, J. S., Correa-Oliveira, R., Croese, J., & Bethony, J. M. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.88 · Cited by 322
Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control
Utzinger, J., & Keiser, J. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.2.263 · Cited by 329
Metadata
- Authors
- Dayan, A. D.
- Affiliations
- World Health Organization (CH)
- Corresponding author
- Dayan, A.D
- ORCID
- Dayan, A.D
- Venue
- Acta Tropica
- Publisher
- Elsevier BV
- Published
- 2003-05
- Volume
- 86
- Issue
- 2-3
- Pages
- 141-159
- ISSN
- 0001-706X (ISSN-L)
- OpenAlex
- W2062166509
- Semantic Scholar
- de049c02134397ed9609978bd3e6f4518c3bc247
- Cited by
- 371
- References
- 43
- Citations by year
- 2026: 14 · 2025: 14 · 2024: 15 · 2023: 20 · 2022: 27 · 2021: 35 · 2020: 29 · 2019: 22 · 2018: 14 · 2017: 24 · 2016: 13 · 2015: 18 · 2014: 19 · 2013: 12 · 2012: 12
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Acta Tropica (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Johnson and Johnson
- Topics
- Life Sciences › Immunology and Microbiology › Parasitology › Helminth infection and control
- Health Sciences › Veterinary › Small Animals › Veterinary Pharmacology and Anesthesia
- Health Sciences › Medicine › Infectious Diseases › Parasitic Diseases Research and Treatment
- Keywords
- albendazole, mebendazole, praziquantel, pharmacokinetics, anthelmintics, adverse drug reactions, veterinary drug safety, data gaps, regulatory evaluation
- MeSH terms
- Animals, Anthelmintics, Humans, Mebendazole, Praziquantel, Albendazole, Toxicity Tests
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. https://app.cochat.ai/papers/10.1016/s0001-706x(03)00031-7
- The paper
- Dayan, A. D. (2003). Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Tropica. https://doi.org/10.1016/s0001-706x(03)00031-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.